Press Releases

Companies continue to work collaboratively to advance NRX-101 through registrational trials NRx remains eligible for an additional $324 million in development and sales milestones, as well as...

Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its...

HOPE Therapeutics is dedicated to bringing NRX-100 (IV Ketamine) for Suicidal Depression to patients Company to be initially owned by NRx and current NRx shareholders via a planned tax-free...

Exceeded originally target enrollment (70) with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter Positive data triggers milestone payment from...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and PTSD, today announced...

NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity 3...

The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing...

Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024 RADNOR, Pa., Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)...

Former Inspector General, US Dept. of Health and Human Services Former Assistant US Attorney for the Eastern District of Virginia Nationally recognized attorney in highly regulated industries;...

Ketamine, an NMDA blocker, was highly effective compared to active comparator in rapidly reducing Suicidality (p=0.0003) This study represents the second well-controlled trial NRx has licensed...

"Study May Proceed" letter received from FDA Potential to initiate registrational study in 2024 RADNOR, Pa., Dec. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced their 2023 Annual Meeting of Stockholders (the "Annual...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Founder and Chief Scientist...

Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted 70 patients in the Phase 2b/3 trial of...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial...

No current FDA-approved formulation of ketamine for treatment of depression and suicidality Partners are developing a proprietary, tamper and diversion-resistant formulation and packaging Finished...

FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has...

"Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate...

Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify for insurance reimbursement Need for...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx...

Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of...

Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.

Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to present the data to FDA with a goal of identifying a path to an NDA RADNOR, Pa., Sept. 15, 2023...

Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa., Sept. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.

NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine model D-cycloserine (DCS), a key component of NRX-101, was...

IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with...

NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.40; shares convert to one common share and one common warrant ($0.40/ strike)...

Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in...

NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D., Chief Executive Officer and Dr.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has closed its previously announced...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements for...

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update...

Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National educational campaign launched to...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, a Delaware Corporation, today announced that it will release its first...

Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical trial in suicidal...

· The independent Data Safety Monitoring Board recommended continuation of patient enrollment as planned · No safety or futility signals were reported in the first 50 patients · This patient...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it will release its...

NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. Offering will assist the Company to initiate its National Treatment Protocol and Safety Database for...

Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and...

FDA discussed a broader indication of "treatment of recently acutely suicidal patients" with Bipolar Depression. This broader indication does not require ketamine as the only stabilization agent....

The Independent Data Safety Monitoring Board identified no safety concerns and issued a recommendation to continue trial enrollment. No treatment-related Serious Adverse Events with first 50...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its...